Arkolith/Insider Trading/BTAI/Form 4

Steinhart Richard I

Chief Financial OfficerBioXcel Therapeutics, Inc. (BTAI) · full profile →Form 4 · filed May 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7K
Net Open-Market Flow
-$7K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 20, 2026Sell(S)7K$1.08$7K26K
May 4, 2026Option exercise(M)18K——33K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 4, 2026Option exercise(M)18K—$053K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-065838) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML